Substance / Medication

Griseofulvin

Overview

Active Ingredient
griseofulvin
RxNorm CUI
5021

Indications

Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis, Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum Epidermophyton floccosum. not Ultramicrosize griseofulvin tablets are indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (a

Labeler: Amneal Pharmaceuticals of New York LLCUpdated: 2025-12-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Two cases of conjoined twins have been reported since 1977 in patients taking griseofulvin during the first trimester of pregnancy. Griseofulvin should not be prescribed to pregnant patients. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential haza

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis.
Tey Hong Liang, Tan Andy Soon Leong, Chan Yuin Chew · J Am Acad Dermatol · 2011
PMID: 21334096Meta-Analysis
Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis.
Gupta Aditya K, Cooper Elizabeth A, Bowen Jenna E · J Drugs Dermatol · 2008
PMID: 18459518Meta-Analysis
Treatment of tinea capitis - griseofulvin versus fluconazole - a comparative study.
Shemer Avner, Plotnik Ira Bernstein, Davidovici Batya et al. · J Dtsch Dermatol Ges · 2013
PMID: 23575220RCT
In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin.
Ahmed Iman Saad, Aboul-Einien Mona Hassan · Eur J Pharm Sci · 2007
PMID: 17628451RCT
Synthetic peptides against Trichophyton mentagrophytes and T. rubrum: Mechanisms of action and efficiency compared to griseofulvin and itraconazole.
Lima Patrícia G, Souza Pedro F N, Freitas Cleverson D T et al. · Life Sci · 2021
PMID: 33238167Observational
Solid phospholipid nano-particles: investigations into formulation and dissolution properties of griseofulvin.
Brinkmann-Trettenes Ulla, Bauer-Brandl Annette · Int J Pharm · 2014
PMID: 24614583Observational
Development and validation of a reversed phase liquid chromatographic method for analysis of griseofulvin and impurities.
Kahsay Getu, Adegoke Aremu Olajire, Van Schepdael Ann et al. · J Pharm Biomed Anal · 2013
PMID: 23518305Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Griseofulvin (substance)
SNOMED CT
372807004
UMLS CUI
C0018242
RxNorm CUI
5021
Labeler
Amneal Pharmaceuticals of New York LLC

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.